Pharming (PHAR) Receivables - Net (2019 - 2026)

Pharming (PHAR) has 8 years of Receivables - Net data on file, last reported at $57.0 million in Q2 2026.

• Quarterly Receivables - Net rose 6.85% year-over-year to $57.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $57.0 million (up 6.85% YoY) and the FY2025 annual result came in at $54.7 million, changed 0.22% from the prior year.
• Receivables - Net eased to $57.0 million in Q2 2026, from $60.0 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $60.0 million in Q1 2026 to a low of $28828.0 in Q3 2022.
• A 5-year average of $41.9 million and a median of $44.9 million in 2023 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net sank 99.91% — and 2023, when it soared 140461.26%.
• Tracing PHAR's Receivables - Net over 5 years: stood at $27.6 million in 2022, then jumped by 67.12% to $46.2 million in 2023, then gained by 18.77% to $54.8 million in 2024, then dropped by 0.22% to $54.7 million in 2025, then climbed by 4.16% to $57.0 million in 2026.
• The last three Receivables - Net figures came in at $57.0 million (Q2 2026), $60.0 million (Q1 2026), and $54.7 million (Q4 2025), per Business Quant data.